The Health Insurance Policy Review Committee (HIPRC) approved the "Improvement Plan for the Health Insurance Drug Pricing System" on March 26, which will reduce the health insurance drug prices for generics by up to 16%. In response, the pharmaceutical and bio industry immediately expressed regret and urged the government to take supplementary measures.


On the 10th, an emergency press conference of the Emergency Committee for Drug Price System Reform for the Development of the Pharmaceutical and Bioindustry was held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Kwak Min-jae

On the 10th, an emergency press conference of the Emergency Committee for Drug Price System Reform for the Development of the Pharmaceutical and Bioindustry was held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Kwak Min-jae

View original image

The Emergency Committee for Reforming the Drug Pricing System for the Development of the Pharmaceutical and Bio Industry (the Emergency Committee) issued a statement on the same day, stating, "The industry’s realistic limit of acceptability is a maximum reduction of 10%. We regret the decision to set the base rate for price reduction at 16%, which exceeds this limit."


The Emergency Committee stated, "Major pharmaceutical companies, which mainly produce domestically developed prescription drugs, are already facing difficult management conditions, with their average operating margin at only around 5%. This significant drug price reduction will make it even harder for domestic pharmaceutical companies to survive." The committee further noted, "Many pharmaceutical companies have already entered emergency management mode, reducing research and development and facility investment plans, completely readjusting hiring plans, or seeking alternative raw materials to cut costs, making such unavoidable measures a reality."


Regarding the preferential pricing measures in the reform plan—such as direct production of raw materials, use of domestic raw materials for national essential drugs, and direct production of injectable antibiotics and pediatric medicines—as well as the phased implementation, the Emergency Committee assessed them as "meaningful policies that can contribute to public health." However, it added, "The phased implementation, which sequentially applies drug price reductions by dividing targets into drugs listed before 2012 and those listed after, may help disperse the shock to the industry, but the overall scale of damage to the industry remains unchanged."


The Emergency Committee emphasized, "The business environment is rapidly deteriorating due to rising oil prices, exchange rates, and shipping costs, as well as increasing instability in the supply of raw materials, amid growing global uncertainties such as the Middle East crisis. Implementing such a large-scale drug price reduction at this time will make it even harder for domestic pharmaceutical companies to survive."



The Emergency Committee urged, "Even after the fact, the government should thoroughly analyze the impact of this reform plan on the industry and make careful adjustments and improvements so that Korea’s pharmaceutical and bio industry can fulfill its essential role without disruption." The committee also expressed hope that "the forthcoming public-private consultative body will play a more concrete and practical role, not only in drug pricing policy but also in improving distribution structures such as CSOs (pharmaceutical sales agents) and devising measures to revitalize generics."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing